GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., ...More

LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 148
  • Publication Date: 2020
  • Doi Number: 10.1016/j.lungcan.2020.07.022
  • Journal Name: LUNG CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
  • Page Numbers: pp.48-54
  • Keywords: Lorlatinib, Real-world data, ALK, ROS1, CELL LUNG-CANCER, HYBRID CAPTURE, SINGLE-ARM, OPEN-LABEL, CRIZOTINIB, REARRANGEMENT, IMMUNOHISTOCHEMISTRY, MULTICENTER, CRITERIA, RET
  • Dokuz Eylül University Affiliated: Yes

Abstract

Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.